Pfizer Inc. (NYSE:PFE) has been a longtime favorite among investors due to its dividend. Despite being kicked off Dow Jones as it was replaced by the biotech company Amgen, Inc. (NASDAQ:AMGN), it is still one of the best bets when it comes to the COVID-19 vaccine. Yet, latest news reports that COVID-19 vaccine candidates being developed by Moderna Inc (NASDAQ:MRNA) and BioNTech SE (NASDAQ:BNTX) and Pfizer itself will require stringent standards for refrigeration. This factor could hamper how they are distributed. Unsurprisingly, stocks tumbled. On the other hand, there are about half a dozen COVID-19 vaccine candidates in clinical trials in the U.S but not all of them are mRNA vaccines. The vaccine being developed by AstraZeneca plc (NYSE:AZN) and the University of Oxford is a recombinant viral vector vaccine whereas the Inovio Pharmaceutical Inc's (NASDAQ:INO) candidate is DNA-based. Competitive positioning will be greatly influenced by storage and delivery conditions. But Pfizer has its background and precious experiences in vaccines which greatly increase its odds of success.
